Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Novo Nordisk realigns

Novo Nordisk A/S is planning to separate its healthcare businesses from its enzymes business to enable it to participate in industry consolidation, as the company's board has finally bowed to shareholder pressure to make

Read the full 344 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers